Published On: 6/9/2025
DDG 2025 Research: Presentation by Michael Roden, MD
Target RWE is proud to feature a significant new study presented at DDG 2025 by our esteemed MASH Steering Committee member, Dr. Michael Roden. Titled "Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH in a real-world setting," this research delves into the critical impact of liver biopsy fibrosis stage and its dynamic changes over time on severe clinical outcomes in MASLD/MASH patients.
Utilizing robust real-world data, this study offers invaluable insights into how disease progresses outside of controlled clinical trial environments, providing a deeper understanding of patient journeys and the long-term implications of fibrosis. View Dr. Roden's compelling video presentation to explore these findings further.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
McKinley Peter
Digital Marketing Specialist
+1 (352) 514-8045
More News
-
06/09/2025
DDG 2025 Research: Presentation by Michael Roden, MD -
05/09/2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research -
05/08/2025
EASL 2025 Research: Presentation by Michael Roden, MD -
05/05/2025
Ed Seguine Appointed CEO of Target RWE -
04/25/2025
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?